FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2933425479> ?p ?o ?g. }

• W2933425479 endingPage "e335" @default.
• W2933425479 startingPage "e329" @default.
• W2933425479 abstract "Combinations of therapies may enhance therapeutic effects without significantly increasing the incidence of adverse events. However, there are few data regarding survival after concomitant chemotherapy and peptide receptor radionuclide therapy (PRRT) with [Lu]Lu-octreotate in patients with neuroendocrine tumors (NETs). Thus, we explored the outcome of this combination of therapies.Fifteen patients with somatostatin receptor-positive, rapidly progressive G2/G3 NETs during chemotherapy or PRRT alone from 2 German cancer centers were included in the retrospective analysis. The patients received a combination of PRRT and chemotherapy with temozolomide (n = 3) or temozolomide plus capecitabine (n = 12). To evaluate the effects of the combined treatment, we assessed the responses, survival, and adverse events.The cumulative administered activity of [Lu]Lu-octreotate had a median of 21.3 GBq after 3 cycles of combination therapy. The patients exhibited a median progression-free survival of 7.1 months and a median overall survival of 25.3 months. The clinical benefit (objective response and stable disease) rates were as follows: 55% of patients according to CT, 38% in [F]F-FDG PET/CT, and 44% in [Ga]Ga-DOTATOC PET/CT. One patient with rapidly progressing liver metastases experienced grade 4 liver failure according to the Common Terminology Criteria for Adverse Events (version 5.0). Four other patients (27%) experienced significantly elevated (grade 3) liver parameters.According to different imaging modalities, the combination of PRRT and temozolomide +/- capecitabine led to disease control in 38% to 55% of the progressive NETs after PRRT or chemotherapy alone failed. The overall survival in this extensively pretreated group of patients was nearly 25 months. The majority of patients did not experience any serious adverse events." @default.
• W2933425479 created "2019-04-11" @default.
• W2933425479 creator A5001442023 @default.
• W2933425479 creator A5003820676 @default.
• W2933425479 creator A5009102592 @default.
• W2933425479 creator A5012867413 @default.
• W2933425479 creator A5014277422 @default.
• W2933425479 creator A5017611331 @default.
• W2933425479 creator A5024581793 @default.
• W2933425479 creator A5032614405 @default.
• W2933425479 creator A5067116615 @default.
• W2933425479 creator A5076041681 @default.
• W2933425479 creator A5083642995 @default.
• W2933425479 date "2019-05-01" @default.
• W2933425479 modified "2023-10-01" @default.
• W2933425479 title "Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors" @default.
• W2933425479 cites W1988986189 @default.
• W2933425479 cites W2003672751 @default.
• W2933425479 cites W2008997722 @default.
• W2933425479 cites W2009629472 @default.
• W2933425479 cites W2012856564 @default.
• W2933425479 cites W2042293638 @default.
• W2933425479 cites W2057241215 @default.
• W2933425479 cites W2077081075 @default.
• W2933425479 cites W2088344186 @default.
• W2933425479 cites W2100276373 @default.
• W2933425479 cites W2128544796 @default.
• W2933425479 cites W2140741951 @default.
• W2933425479 cites W2155263737 @default.
• W2933425479 cites W2158474413 @default.
• W2933425479 cites W2158476626 @default.
• W2933425479 cites W2158749901 @default.
• W2933425479 cites W2170707038 @default.
• W2933425479 cites W2229261843 @default.
• W2933425479 cites W2278280755 @default.
• W2933425479 cites W2291637351 @default.
• W2933425479 cites W2573369749 @default.
• W2933425479 cites W2578972525 @default.
• W2933425479 cites W2593603796 @default.
• W2933425479 cites W2597139737 @default.
• W2933425479 cites W2625330427 @default.
• W2933425479 cites W2771839629 @default.
• W2933425479 cites W2897549551 @default.
• W2933425479 doi "https://doi.org/10.1097/rlu.0000000000002532" @default.
• W2933425479 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30932975" @default.
• W2933425479 hasPublicationYear "2019" @default.
• W2933425479 type Work @default.
• W2933425479 sameAs 2933425479 @default.
• W2933425479 citedByCount "41" @default.
• W2933425479 countsByYear W29334254792019 @default.
• W2933425479 countsByYear W29334254792020 @default.
• W2933425479 countsByYear W29334254792021 @default.
• W2933425479 countsByYear W29334254792022 @default.
• W2933425479 countsByYear W29334254792023 @default.
• W2933425479 crossrefType "journal-article" @default.
• W2933425479 hasAuthorship W2933425479A5001442023 @default.
• W2933425479 hasAuthorship W2933425479A5003820676 @default.
• W2933425479 hasAuthorship W2933425479A5009102592 @default.
• W2933425479 hasAuthorship W2933425479A5012867413 @default.
• W2933425479 hasAuthorship W2933425479A5014277422 @default.
• W2933425479 hasAuthorship W2933425479A5017611331 @default.
• W2933425479 hasAuthorship W2933425479A5024581793 @default.
• W2933425479 hasAuthorship W2933425479A5032614405 @default.
• W2933425479 hasAuthorship W2933425479A5067116615 @default.
• W2933425479 hasAuthorship W2933425479A5076041681 @default.
• W2933425479 hasAuthorship W2933425479A5083642995 @default.
• W2933425479 hasConcept C121608353 @default.
• W2933425479 hasConcept C126322002 @default.
• W2933425479 hasConcept C143998085 @default.
• W2933425479 hasConcept C197934379 @default.
• W2933425479 hasConcept C2776694085 @default.
• W2933425479 hasConcept C2777389519 @default.
• W2933425479 hasConcept C2777793932 @default.
• W2933425479 hasConcept C2777909004 @default.
• W2933425479 hasConcept C2778822529 @default.
• W2933425479 hasConcept C2779066768 @default.
• W2933425479 hasConcept C2779384505 @default.
• W2933425479 hasConcept C2993559085 @default.
• W2933425479 hasConcept C526805850 @default.
• W2933425479 hasConcept C71924100 @default.
• W2933425479 hasConceptScore W2933425479C121608353 @default.
• W2933425479 hasConceptScore W2933425479C126322002 @default.
• W2933425479 hasConceptScore W2933425479C143998085 @default.
• W2933425479 hasConceptScore W2933425479C197934379 @default.
• W2933425479 hasConceptScore W2933425479C2776694085 @default.
• W2933425479 hasConceptScore W2933425479C2777389519 @default.
• W2933425479 hasConceptScore W2933425479C2777793932 @default.
• W2933425479 hasConceptScore W2933425479C2777909004 @default.
• W2933425479 hasConceptScore W2933425479C2778822529 @default.
• W2933425479 hasConceptScore W2933425479C2779066768 @default.
• W2933425479 hasConceptScore W2933425479C2779384505 @default.
• W2933425479 hasConceptScore W2933425479C2993559085 @default.
• W2933425479 hasConceptScore W2933425479C526805850 @default.
• W2933425479 hasConceptScore W2933425479C71924100 @default.
• W2933425479 hasIssue "5" @default.
• W2933425479 hasLocation W29334254791 @default.
• W2933425479 hasLocation W29334254792 @default.
• W2933425479 hasOpenAccess W2933425479 @default.

• next